Literature DB >> 8774659

Effects of irradiation on the expression of surface antigens in human ovarian cancer.

A D Santin1, J C Hiserodt, J Fruehauf, P J DiSaia, S Pecorelli, G A Granger.   

Abstract

Tumor cells from four established human ovarian carcinoma cell lines were analyzed for their expression of surface antigens including MHC Class I, Class II, ICAM-1, and the tumor-associated antigens CA 125 and Her2-neu before and after exposure to high doses of gamma irradiation. All four ovarian cell IInes expressed variable levels of MHC Class I and Her2-neu. ICAM-1 antigens were expressed in only two cell lines and Class II and CA 125 surface antigens were absent in all the cell lines evaluated. Exposure to high doses of gamma irradiation (i.e., 5000 to 10,000 cGy) significantly and consistently increased the expression of all surface antigens present on the cells prior to irradiation. Importantly, the irradiation-induced upregulation was persistent and lasted until all the cells died. Irradiation was unable to induce neoexpression of antigens previously not expressed by the cells (i.e., MHC Class II or ICAM-1). These findings may partially explain the increased immunogenicity of tumor cells following irradiation and may suggest enhanced immune recognition in tumor tissue in patients receiving radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774659     DOI: 10.1006/gyno.1996.0075

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors.

Authors:  Maurizio Chiriva-Internati; Fabio Grizzi; Justin Pinkston; K John Morrow; Nicholas D'Cunha; Eldo E Frezza; Pier Carlo Muzzio; W Martin Kast; Everardo Cobos
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Mar-Apr       Impact factor: 2.416

2.  Radiation-induced tumor neoantigens: imaging and therapeutic implications.

Authors:  Christopher D Corso; Arif N Ali; Roberto Diaz
Journal:  Am J Cancer Res       Date:  2011-01-25       Impact factor: 6.166

Review 3.  Combining radiotherapy and immunotherapy: a revived partnership.

Authors:  Sandra Demaria; Nina Bhardwaj; William H McBride; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

Review 4.  Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.

Authors:  Ananthan Sadagopan; Theodoros Michelakos; Gabriella Boyiadzis; Cristina Ferrone; Soldano Ferrone
Journal:  JAMA Oncol       Date:  2022-03-01       Impact factor: 31.777

5.  T lymphocytes and normal tissue responses to radiation.

Authors:  Dörthe Schaue; William H McBride
Journal:  Front Oncol       Date:  2012-09-19       Impact factor: 6.244

6.  Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer.

Authors:  Zhu Alexander Cao; Dylan Daniel; Douglas Hanahan
Journal:  BMC Cancer       Date:  2002-05-03       Impact factor: 4.430

Review 7.  Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.

Authors:  Xinxin Zhu; Jinghe Lang
Journal:  J Gynecol Oncol       Date:  2017-06-05       Impact factor: 4.401

Review 8.  A Century of Radiation Therapy and Adaptive Immunity.

Authors:  Dörthe Schaue
Journal:  Front Immunol       Date:  2017-04-11       Impact factor: 7.561

9.  Regulatory T cells in radiotherapeutic responses.

Authors:  Dörthe Schaue; Michael W Xie; Josephine A Ratikan; William H McBride
Journal:  Front Oncol       Date:  2012-08-17       Impact factor: 6.244

Review 10.  The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.

Authors:  Kimberly M Arnold; Nicole J Flynn; Adam Raben; Lindsay Romak; Yan Yu; Adam P Dicker; Firas Mourtada; Jennifer Sims-Mourtada
Journal:  Cancer Growth Metastasis       Date:  2018-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.